TERN — Terns Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Kenneth Griffin Reports 5.3% Passive Stake In Terns Pharmaceuticals As Of July 10
Terns Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Terns Pharmaceuticals Q1 Net Income USD -22.373 Million Vs. IBES Estimate USD -24.8 Million
Brief: Terns Pharmaceuticals Announces Leadership Changes
Brief: Terns Pharmaceuticals Announces Data From Ongoing Phase 1 Pharmacokinetic Study Of Allosteric Bcr-Abl Inhibitor Tern-701
Brief: Terns Pharmaceuticals Q4 Net Income USD -21.019 Million
Brief: Terns Pharmaceuticals Announces Orphan Drug Designation Granted To TERN-701
Brief: Terns Pharmaceuticals Q3 Net Income USD -29.767 Million
Brief: Terns Pharmaceuticals Presents Late-Breaking Data From Phase 2A Duet Trial
Terns Pharmaceuticals Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design Of TERN-701 For The Treatment Of Chronic Myeloid Leukemia
Terns Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Terns Pharmaceuticals, Inc. posts Q2 basic EPS USD -0.25
Terns Pharmaceuticals Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Terns Pharmaceuticals Announces Leadership Transition
U.S. RESEARCH ROUNDUP-Albemarle, Ellington Financial, Savara
Terns Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Terns Pharmaceuticals Reports First Quarter 2023 Financial Results And Corporate Updates
Terns Pharmaceuticals Inc expected to post a loss of 27 cents a share - Earnings Preview